Company intelligence / Profile preview

Nova Satra Dx

Singapore, Central Region, Singapore

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Nova Satra Dx developed and commercially launched blood-based, epigenetics-driven diagnostic tests (e.g., NovoTect BC) for early detection of cancers, primarily in Asian women, and in 2019 merged with INEX Innovations Exchange to form INEX Innovate, which continues to market and expand these diagnostics in Asia-Pacific.

Therapeutic areas: OncologyRare Diseases
Modalities: Diagnostic testIn vitro diagnostic
Industry: Molecular Diagnostics

Partnerships

University of Oxford (origin of NovoTect technology)Genting Berhad (via Genting Bio Cellular as strategic investor/partner)Enterprise Singapore/SEEDS CapitalSNS Holdings/ZIG Ventures ecosystem partnerships

Beyond the preview

Go deeper on Nova Satra Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nova Satra Dx.

Explore the full profile